Biosimilar insulin and insulin prices: What does this mean for Kyrgyzstan

For people living with diabetes, affordable and reliable access to insulin is essential.

Developed by Health Policy Analysis, this policy brief examines the growing role of biosimilar insulins and compares their government procurement prices with those of originator products in Kyrgyzstan. Focusing on insulin Aspart and Glargine, it explores how carefully expanding the use of lower-cost biosimilars could increase competition, make better use of public resources and support more sustainable access to life-saving treatment.